Systems Toxicology Approach to Identifying Paracetamol Overdose

Paracetamol (acetaminophen (APAP)) is one of the most commonly used analgesics in the United Kingdom and the United States. However, exceeding the maximum recommended dose can cause serious liver injury and even death. Promising APAP toxicity biomarkers are thought to add value to those used currently and clarification of the functional relationships between these biomarkers and liver injury would aid clinical implementation of an improved APAP toxicity identification framework. The framework currently used to define an APAP overdose is highly dependent upon time since ingestion and initial dose; information that is often highly unpredictable. A pharmacokinetic/pharmacodynamic (PK/PD) APAP model has been built in order to understand the relationships between a panel of biomarkers and APAP dose. Visualization and statistical tools have been used to predict initial APAP dose and time since administration. Additionally, logistic regression analysis has been applied to histology data to provide a prediction of the probability of liver injury.

[1]  Airfares 2002Q,et al.  MULTIPLE LINEAR REGRESSION , 2006, Statistical Methods for Biomedical Research.

[2]  Julian Blagg,et al.  The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore , 2007, Journal of Pharmacology and Experimental Therapeutics.

[3]  D. Antoine,et al.  Redox-Dependent HMGB1 Isoforms as Pivotal Co-Ordinators of Drug-Induced Liver Injury: Mechanistic Biomarkers and Therapeutic Targets. , 2016, Antioxidants & redox signaling.

[4]  S. Bhattacharyya,et al.  Translational biomarkers of acetaminophen-induced acute liver injury , 2015, Archives of Toxicology.

[5]  William M. Lee,et al.  Acetaminophen‐induced acute liver failure: Results of a United States multicenter, prospective study , 2005, Hepatology.

[6]  Laurens van der Maaten,et al.  Accelerating t-SNE using tree-based algorithms , 2014, J. Mach. Learn. Res..

[7]  D. Reith,et al.  Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand , 2015, The Medical journal of Australia.

[8]  Mitchell R. McGill,et al.  Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. , 2012, Journal of hepatology.

[9]  John C Lindon,et al.  Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. , 2004, Journal of pharmaceutical and biomedical analysis.

[10]  Dominic P. Williams,et al.  Timescale analysis of a mathematical model of acetaminophen metabolism and toxicity. , 2015, Journal of theoretical biology.

[11]  C. Metzler.  Usefulness of the Two-Compartment Open Model in Pharmacokinetics , 1971 .

[12]  Frederick R Adler,et al.  Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: Early discrimination between survival and death , 2012, Hepatology.

[13]  Viv Bewick,et al.  Statistics review 14: Logistic regression , 2005, Critical care.

[14]  D. Antoine.  Laboratory‐based biomarkers to improve causality assessment in drug‐induced liver injury , 2017, Clinical liver disease.

[15]  Dominic P. Williams,et al.  High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Hartmut Jaeschke,et al.  Acetaminophen-induced Liver Injury: from Animal Models to Humans , 2014, Journal of clinical and translational hepatology.

[17]  J. Dear,et al.  How to treat paracetamol overdose and when to do it , 2016, Expert review of clinical pharmacology.

[18]  M. Pirmohamed,et al.  Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies , 2017, The lancet. Gastroenterology & hepatology.

[19]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[20]  Margaret H. Wright,et al.  Nelder, Mead, and the other simplex method , 2012 .

[21]  D. Webb,et al.  Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial , 2014, The Lancet.

[22]  William Ribarsky,et al.  Understanding Principal Component Analysis Using a Visual Analytics Tool , 2009 .

[23]  D. Webb,et al.  Effect of the UK’s revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment , 2014, British journal of clinical pharmacology.

[24]  Kristin L. Sainani,et al.  Logistic Regression , 2014, PM & R : the journal of injury, function, and rehabilitation.

[25]  A. Kipar,et al.  Dynamic and accurate assessment of acetaminophen‐induced hepatotoxicity by integrated photoacoustic imaging and mechanistic biomarkers in vivo , 2017, Toxicology and applied pharmacology.

[26]  Walter T. Ambrosius,et al.  Topics in Biostatistics , 2007, Methods in Molecular Biology™.

[27]  G. Gerken,et al.  Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute‐on‐chronic liver failure , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[28]  P. Watkins,et al.  Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses , 2017, Gene regulation and systems biology.

[29]  L. James,et al.  Mechanisms of acetaminophen-induced liver necrosis. , 2010, Handbook of experimental pharmacology.

[30]  G. Koch,et al.  Acetaminophen overdose. 662 cases with evaluation of oral acetylcysteine treatment. , 1981 .

[31]  N. Medlicott,et al.  SIMULTANEOUS MODELLING OF THE MICHAELIS‐MENTEN KINETICS OF PARACETAMOL SULPHATION AND GLUCURONIDATION , 2009, Clinical and experimental pharmacology & physiology.

[32]  Rotem Ben-Shachar,et al.  The biochemistry of acetaminophen hepatotoxicity and rescue: a mathematical model , 2012, Theoretical Biology and Medical Modelling.

[33]  A. L. Bloomfield,et al.  Liver-function tests. , 1954, A.M.A. archives of internal medicine.

[34]  Alasdair J Gray,et al.  Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital , 2013, Hepatology.

[35]  Vincenzo Savarino,et al.  Liver enzyme alteration: a guide for clinicians , 2005, Canadian Medical Association Journal.

[36]  S. Siler,et al.  Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials , 2017, Clinical pharmacology and therapeutics.

[37]  Klaus Mauch,et al.  A Multi-Scale Modeling Framework for Individualized, Spatiotemporal Prediction of Drug Effects and Toxicological Risk , 2013, Front. Pharmacol..

[38]  J. Dear,et al.  Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon? , 2016, Expert opinion on drug safety.

[39]  R. Andrade,et al.  Drug-induced hepatotoxicity , 2003, The New England journal of medicine.